PACTG 1034: PROTEASE-CONTAINING AND PROTEASE-SPARING HAART REGIMENS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 设计：第三阶段，开放标签，随机 样本规模：240名受试者 人群：感染艾滋病毒的青少年，无论感染途径如何，年龄在13至23岁之间，艾滋病毒RNA和GT；10,000拷贝/毫升，并认为受试者的初级保健提供者建议对他们进行抗逆转录病毒治疗。受试者可以接受抗逆转录病毒治疗，也可以接受单一方案的联合治疗，包括使用或不使用单一PI的NRTI(洛匹那韦除外)。除了怀孕期间接受ZDV单一治疗外，他们一生中可能没有接受过超过一种方案。受试者必须服用非核苷类逆转录酶抑制物(NNRTI)。 分层：所有受试者将根据以前的抗逆转录病毒暴露(绝对纳米级或抗逆转录病毒暴露)进行分层。 学习时间：96周。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. DESIGN: Phase III, open-label, randomized SAMPLE SIZE: 240 subjects POPULATION: HIV-infected adolescents, regardless of route of infection, who are 13 to 23 years of age with HIV RNA >10,000 copies/ml and for whom antiretroviral treatment is felt to be indicated by a subject's primary care provider. Subjects may be nanve to antiretroviral therapy, or may have received a single regimen of combination therapy, consisting of NRTIs with or without a single PI (except lopinavir). They may not have received more than a single regimen in their lifetime with the exception of ZDV monotherapy during pregnancy. Subjects must be nanve to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class. STRATIFICATION: All subjects will be stratified by previous antiretroviral exposure (absolutely nanve or antiretroviral exposed). DURATION OF STUDY: Ninety-six weeks.